Novo Nordisk Announces FDA Approves Levemir® for Expanded Use in Children Two to Five Years of Age with Type 1 Diabetes
Novo Nordisk (NYSE: NVO) announced today that the U.S. Food and Drug Administration (FDA) has approved Levemir® (insulin detemir [rDNA origin] injection) for use in children ages two to five years with type 1 diabetes. With the expansion of its pediatric indication, Levemir® is now available for type 1 diabetes patients from age two through adulthood and adult patients with type 2 diabetes.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.